Literature DB >> 25563663

Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis.

Takafumi Nishimura1, Yuji Inaba2, Yozo Nakazawa1, Taku Omata3, Manami Akasaka4, Ikuko Shirai5, Motoki Ichikawa6.   

Abstract

OBJECTIVE: Myasthenia gravis (MG) is a T-cell dependent and antibody mediated autoimmune disease. Recent studies of adult patients and animal models have shown that regulatory T cells (Tregs) play an important role in the pathogenesis of MG, but little is known about MG in children. This study evaluated the role of peripheral blood Tregs in childhood ocular MG and assessed if Tregs could be an index for estimating immunological status. PATIENTS AND METHODS: Clinical data and peripheral lymphocytes were obtained from 13 children with serum AChR antibody-positive ocular type MG and 18 age-matched controls. Committed cells from MG patients were divided into two clinical stages: active (n=12) and remission (n=11). Tregs and Th17 cells were analyzed by flow cytometric analysis based on CD4(+)CD25(+) intracellular Foxp3(+) and CD4(+) intracellular IL-17A(+) fractions, respectively.
RESULTS: The percentage of Tregs among peripheral blood CD4(+) T cells in active stage, remission stage, and control groups was 3.3±1.3%, 4.8±1.7%, and 5.0±0.6%, respectively. The Treg population was significantly lower in the active stage than in the remission stage and controls. Furthermore, Treg percentage was significantly lower during relapse of myasthenia symptoms. We witnessed no remarkable associations between the percentage of Tregs and immune suppressant dosages.
CONCLUSIONS: A significant reduction in the peripheral Treg population is considered to contribute to the pathophysiology of ocular type childhood MG and may be a marker of immunological state in these patients.
Copyright © 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Childhood; Myasthenia gravis; Ocular type; Regulatory T cell (Treg); Relapse; Th17 cell

Mesh:

Year:  2015        PMID: 25563663     DOI: 10.1016/j.braindev.2014.12.007

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  2 in total

Review 1.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

2.  Clinical Features and Prognosis of Ocular Myasthenia Gravis Patients with Different Phenotypes.

Authors:  Li-Li Wang; Yun Zhang; Mao-Lin He
Journal:  Chin Med J (Engl)       Date:  2015-10-05       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.